Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defining aggressive prostate cancer using a 12-gene model.

Tarek A Bismar1, Francesca Demichelis, Alberto Riva

  • 1Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Neoplasia (New York, N.Y.)
|March 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial transcriptomic mapping of canine osteosarcoma reveals immune microenvironment features linked to survival.

Communications biology·2026
Same author

CholeraSeq: a comprehensive genomic pipeline for cholera surveillance and near real-time outbreak investigation.

Bioinformatics (Oxford, England)·2025
Same author

Intrinsic Alterations of the Inflammatory Pathways in Primary Canine Atopic Keratinocytes.

Allergy·2025
Same author

Sex Differences in Brain Transcriptomes of Juvenile Cynomolgus Macaques.

Biomolecules·2025
Same author

Deletion of metal transporter Zip14 reduces major histocompatibility complex II expression in murine small intestinal epithelial cells.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Phylogenetic-informed graph deep learning to classify dynamic transmission clusters in infectious disease epidemics.

Bioinformatics advances·2024

Researchers identified 12 key proteins to distinguish aggressive prostate cancer from indolent forms. This protein signature accurately predicts cancer progression in patients, improving diagnostic accuracy for prostate cancer.

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Proteomics

Background:

  • Distinguishing aggressive prostate cancer from indolent disease remains a critical clinical challenge.
  • Current diagnostic methods require improvement for accurate prognostication.

Purpose of the Study:

  • To identify and validate a panel of biomarkers capable of predicting prostate cancer progression.
  • To develop a robust model for differentiating aggressive from indolent prostate cancer.

Main Methods:

  • Utilized proteomic and expression array data to identify 36 dysregulated genes.
  • Applied linear discriminant analysis to select an optimal 12-protein predictive model.
  • Validated the model using transcriptional levels of the 12 genes in a separate patient cohort.

Related Experiment Videos

Main Results:

  • A 12-protein model was identified as optimal for predicting prostate cancer progression.
  • Transcriptional levels of the 12 genes accurately predicted prostate-specific antigen failure in 79 men post-surgery (P = .0015).
  • Cross-platform data integration yielded a robust predictive model.

Conclusions:

  • A 12-protein signature effectively predicts prostate cancer progression and patient outcomes.
  • Cross-platform biomarker models offer a robust approach for clinical prognostication.
  • This study provides a promising tool for distinguishing aggressive from indolent prostate cancer.